The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SimiGon merger to go ahead; Segro launches green bond

Thu, 17th Mar 2022 21:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Segro PLC - FTSE 100-listed industrial property investor - Launches EUR1.15 billion unsecured "green bond" as part of European medium-term note programme. Issue will be split into two tranches: EUR650 million with a four-year term, priced at 70 basis points above euro mid-swaps; and EUR500 million with an eight-year term priced at 110 basis points above euro mid-swaps. Chief Financial Officer Soumen Das says: "The proceeds of this issuance will enable us to continue to respond to our customers’ increased requirements for modern space built to the highest levels of sustainability standards."

----------

Bank of Cyprus Holdings PLC - Nicosia-based lender - Notes it does not have any banking operations in Russia or Ukraine, following the sale of its operations in Ukraine in 2014 and in Russia in 2015. Has a legacy net exposure of about EUR10 million in Russia which is being run down. Has no exposure to Russian bonds or banks which are the subject of EU sanctions, and currently has credit balances in accounts held with subsidiaries of European banks in Russia amounting to about EUR13 million. "Overall, the group expects limited impact from its direct exposure, while any indirect impact will depend on the duration and severity of the crisis and its impact on the Cypriot economy, which remains uncertain at this stage," the bank adds.

----------

Gulf Investment Fund PLC - invests in companies in Gulf Cooperation Council countries - Launches tender offer for own shares. "The tender price will be determined once the company's assets have been allocated between the continuing pool and the tender pool, the assets contained in the tender pool have been fully realised and all the liabilities to be borne by the tender pool have been accounted for," company explains. Notes will limit offer to where it has 38.0 million shares in issue following offer.

----------

Ten Lifestyle Group PLC - London-based lifestyle and travel service platform - Wins "significant" commission from an unnamed existing "major global financial services client" to develop and enhance Ten's proprietary digital platform used by the client's customers. Expects existing contract, which is classified as "extra large" by company as it exceeds GBP5 million, to rise in value of a "medium" contract, valued between GBP250,000 and GBP2 million, over the next 12 months and may be renewed over the following years. Adds: "In this addition to the existing contract, Ten will be paid to develop new features that are expected to increase customer engagement, the number of active users and related revenues. These include the integration of the client's own assets into the existing asset-rich digital platform environment to enhance the overall proposition to the customer base."

----------

Mobile Streams PLC - London-based mobile content provider - Broker option for placing "materially over-subscribed" for by existing shareholders. Demand for broker option at about seven times original minimum at GBP700,000. Allocations were scaled back to GBP350,000 through issue of 116.7 million new shares. Now has 3.11 billion shares in issue. Chief Executive Mark Epstein says: "We are now extremely well-funded, and the business is in the strongest position it has been in for years."

----------

Semper Fortis Esports PLC - London-based professional esports team operator - Launches new blockchain-based play-to-earn gaming division, SMPR Guild. "Play-to-earn is a new category in video gaming that rewards players for winning and completing tasks with game-based tokens which are free to use in-game or convert into cryptocurrency and then into fiat currency," company explains. Company will purchase in-game items, or non-fungible tokens known as NFTs, which are the characters, plots of virtual land, and weapons required to play a game and then provide access to these to active game players on a revenue share basis.

----------

SimiGon Ltd - Israel-based software company - Says Gal Erez, a 4% shareholder in the company, withdraws application for restraining order over firm's merger and share cancellation. Last day of trading will now be March 25, with cancellation from AIM to be March 29. In mid-January, agrees to a merger with Power Breezer Sub Ltd and Maxify Solutions Inc, which will value the company at USD8.5 million. Shareholders in SimiGon are expected to receive 16.5 US cents per share.

----------

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says it progresses its new anti-glycan monoclonal antibody platform GlyMab. Adds: "The company's fourth proprietary platform has the potential to expand further its pipeline of novel anti-cancer mAbs and the versatility to yield other drug formats including antibody drug conjugate and CAR-T candidates. Scancell is developing a unique pipeline of tumour-specific anti-glycan antibodies with the initial aim of generating early-stage clinical data, either alone or in combination with potential strategic partners." Currently has a pipeline of five anti-glycan mAbs.

----------

LungLife AI Inc - Thousand Oaks, California-based developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence - Says "pivotal" clinical study to evaluate the company's LungLB test will now include multiple US Veterans Affairs medical centres, of which the first participant has been enrolled from the Bay Pines VA in Florida. The VA has the US largest integrated health care system. Chief Executive Paul Pagano says: "I am delighted that we will have representation from the VA Healthcare System in our study, as this marks an important step on our journey towards the successful deployment of the LungLB test."

----------

Berkeley Energia Ltd - clean energy company focused on bringing wholly owned Salamanca project in Spain into production - Not aware of any information that would explain recent trading. Closes up 19% in Sydney on Thursday and gains 7.5% in London. "The company notes the recent increase in trading of its shares on the Spanish Stock Exchanges, which has seen an increase in the company's share price by over 70% since March 10 with over 112 million shares traded," it adds. Points to Russia's invasion of Ukraine and the current high energy prices in Europe, particularly in Spain which has seen spot electricity prices increase significantly to record highs in March, there have been news articles in the Spanish and European press referring to nuclear power being assessed as a viable alternative to decrease Europe's dependence on Russian energy.

----------

Hurricane Energy PLC - Surrey, England-based oil producer - Notes Lancaster field produces 263,000 barrels of oil during February, at an average oil rate of 9,394 bopd. Ends February with USD71 million in net free cash, down from USD85 million at end of January. Chief Executive Antony Maris says: "Through a combination of further strong operational performance at Lancaster and continued high commodity prices, coupled with our ongoing constructive discussions with Bluewater over a charter extension for the Aoka Mizu, we continue to build the platform for Hurricane's future."

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.